TransMedics Group, Inc. — Investor Relations & Filings

TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy. The company's primary offering is the Organ Care System (OCS™), a portable extracorporeal warm perfusion and assessment technology. The OCS™ is the only platform approved by the U.S. FDA for preserving donor hearts, lungs, and livers for transplantation, including for Donation after Circulatory Death (DCD) hearts. This system is designed to overcome the time and distance limitations of traditional cold storage, aiming to increase organ utilization, improve clinical outcomes, and reduce transplant costs. TransMedics also provides the National OCS™ Program (NOP™), an end-to-end solution that combines the OCS™ technology with dedicated logistics and expert clinical services to support transplant centers.